A Phase 3 interventional study of Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A) and Placebo in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 3 sites in Russia. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-04.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.
Among the 46 studies testing shingrix in Herpes Zoster, this one is the 9th largest by enrollment, is one of 5 that started in 2019, is one of 22 in phase 3, and was the 27th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
Loyola University · Sites in United States
University of Colorado, Denver · Sites in United States
Ages 18–70
By country, each count listing its studies:
shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 22 · Phase 4 8
First in 2009; this study’s year is marked. 5 started in 2019.
This study's enrollment of 1,430 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 239 across the 46 interventional studies. Of the 32 that completed or were terminated, 27 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
44 studies in Herpes Zoster by GlaxoSmithKline: 3 open now, 5 under way, 1 of them phase 3. Of 39 finished, 34 (87%) have results posted.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 10th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2019, is one of 25 in phase 3, and was the 36th registered.
GlaxoSmithKline’s Herpes Zoster studies by the year they started, since 2007.
4 of the studies testing shingrix in Herpes Zoster that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
| NCT05580458National Institute of Allergy and Infectious Diseases (NIAID)Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population | 2027-02-01 |
| NCT06162494Ann & Robert H Lurie Children's Hospital of ChicagoRecombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients | 2027-03-31 |
| NCT06569823Dynavax Technologies CorporationSafety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies testing shingrix in Herpes Zoster, from their registry updates:
Among GlaxoSmithKline’s 44 in Herpes Zoster:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to assess the safety and immunogenicity of GSK Biologicals' HZ/su vaccine when given on a two-dose schedule to adults aged 50 years and above who had a previous episode of Herpes Zoster (HZ).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with a history of HZ. Confirmation of the prior HZ diagnosis can be done by one of the following three methods:
OR Laboratory diagnosed HZ: OR
Non-childbearing potential is defined as current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy, bilateral salpingectomy or .
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with a prior episode of HZ randomized to the HZ/su group were scheduled to receive 2 doses of HZ/su vaccine, one at Day 1 and one at Month 2.
Biological: Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)
Participants with a prior episode of HZ randomized to the Placebo group were scheduled to receive 2 doses of placebo, one at Day 1 and one at Month 2.
Drug: Placebo
Drug page: Shingrix
2 doses of HZ/su vaccine were administered intramuscularly according to a 0,2 months vaccination schedule, at Day 1 and Month 2.
2 doses of Placebo were administered intramuscularly according to a 0,2 months vaccination schedule, at Day 1 and Month 2.
Incidence Rate of Confirmed Herpes Zoster (HZ) Cases
A suspected case of HZ is defined as a new unilateral rash accompanied by pain (broadly defined to include allodynia, pruritus or other sensations) and no alternative diagnosis. A suspected case of HZ was confirmed by an algorithm that included Polymerase Chain Reaction (PCR) and the HZ Ascertainment Committee (HZAC) determination. The incidence rate (n/T) of confirmed HZ cases, expressed in terms of 1000 person-years rate, was calculated as the number of participants reporting at least one confirmed HZ case (n) in a group, over the sum of follow-up period expressed in years (T) in the same group, and multiplied by 1000.
Time frame: From 30 days post-second vaccination (Month 3) until study end (duration of approximately 2 years to 4 years and 5 months)
Incidence Rate of Confirmed HZ Cases
A suspected case of HZ is defined as a new unilateral rash accompanied by pain (broadly defined to include allodynia, pruritus or other sensations) and no alternative diagnosis. A suspected case of HZ was confirmed by an algorithm that included PCR and the HZAC determination. The incidence rate (n/T) of confirmed HZ cases, expressed in terms of 1000 person-years rate, was calculated as the number of participants reporting at least one confirmed HZ case (n) in a group, over the sum of follow-up period expressed in years (T) in the same group, and multiplied by 1000.
Time frame: From first vaccination (Day 1) until study end (duration of approximately 2 years to 4 years and 5 months)
Number of Participants With Any and Grade 3 Solicited Administration Site Events
Assessed solicited administration site events included erythema, pain, pruritus and swelling at the injection site. Any = occurrence of the event regardless of intensity grade. Grade 3 pain = significant pain at rest, which prevented normal, everyday activities. Grade 3 erythema, swelling = erythema, swelling with a surface diameter greater than (\>) 100 millimeters (mm). Grade 3 pruritus = itchy sensation that prevented normal, everyday activities.
Time frame: Within 7 days after each vaccination (occurring at Day 1 and Month 2)
Duration in Days of Solicited Administration Site Events
Duration is the number of days in which a participant experienced the symptom within the 7-day solicited follow-up period. Assessed solicited administration site events included erythema, pain, pruritus and swelling at the injection site.
Time frame: Within 7 days after each vaccination (occurring at Day 1 and Month 2)
Number of Participants With Any, Grade 3 and Related Solicited Systemic Events
Assessed solicited systemic events included fatigue, fever (defined as axillary temperature greater than or equal to (\>=) 38.0°C/100.4°F), gastrointestinal symptoms, headache, malaise, myalgia, and shivering. Any = occurrence of the event regardless of intensity grade or relation to the study vaccination. Grade 3 = event that prevented normal, everyday activities. Grade 3 fever = axillary temperature higher than (\>) 39.0°C/102.2°F. Related = event assessed by the investigator as related to the study vaccination.
Time frame: Within 7 days after each vaccination (occurring at Day 1 and Month 2)
Duration in Days of Solicited Systemic Events
Duration is the number of days in which a participant experienced the symptom within the 7-day solicited follow-up period. Assessed solicited systemic events included fatigue, fever (defined as axillary temperature \>=38.0°C/100.4°F), gastrointestinal symptoms, headache, malaise, myalgia and shivering.
Time frame: Within 7 days after each vaccination (occurring at Day 1 and Month 2)
Number of Participants With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
An unsolicited AE is defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event. Any = occurrence the event regardless of intensity grade or relation to the study vaccination. Grade 3 = event that prevented normal, everyday activities. Related = event assessed by the investigator as related to the study vaccination.
Time frame: Within 30 days after each vaccination (occurring at Day 1 and Month 2)
Number of Participants With Any and Related Serious Adverse Events (SAEs)
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study participant. Any = occurrence of the SAE regardless of intensity grade or relation to the study vaccination. Related = SAE assessed by the investigator as related to the study vaccination.
Time frame: From first vaccination (Day 1) to 30 days post-last vaccination (last vaccination administered at Day 1 for participants who received only 1 dose and at Month 2 for participants who received 2 doses)
Number of Participants With Any and Related Potential Immune-mediated Diseases (pIMDs)
pIMDs are defined as a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any = occurrence of the pIMD regardless of intensity grade or relation to the study vaccination. Related = pIMD assessed by the investigator as related to the study vaccination.
Time frame: From first vaccination (Day 1) to 30 days post-last vaccination (last vaccination administered at Day 1 for participants who received only 1 dose and at Month 2 for participants who received 2 doses)
Number of Participants With Any and Related SAEs
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study participant. Any = occurrence of the SAE regardless of intensity grade or relation to the study vaccination. Related = SAE assessed by the investigator as related to the study vaccination.
Time frame: From 30 days post-last vaccination until 1 year post-last vaccination (last vaccination administered at Day 1 for participants who received only 1 dose and at Month 2 for participants who received 2 doses)
Number of Participants With Any and Related pIMDs
pIMDs are defined as a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any = occurrence of the pIMD regardless of intensity grade or relation to the study vaccination. Related = pIMD assessed by the investigator as related to the study vaccination.
Time frame: From 30 days post-last vaccination until 1 year post-last vaccination (last vaccination administered at Day 1 for participants who received only 1 dose and at Month 2 for participants who received 2 doses)
Number of Participants With SAEs Related to Investigational Vaccine, Related to Study Participation or to GSK Concomitant Medication/Vaccine
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study participant. Any SAEs related to the investigational vaccine or related to study participation or to a GSK concomitant medication/vaccine as assessed by the investigator are reported.
Time frame: From first vaccination (Day 1) until study end (duration of approximately 2 years to 4 years and 5 months)
Percentage of Participants With Vaccine Response for Anti-glycoprotein E (Anti-gE) Antibodies as Determined by Enzyme Linked Immunosorbent Assay (ELISA)
Vaccine response for anti-gE antibodies is defined as: * For initially seronegative participants, anti-gE antibody concentration at post-vaccination \>= 4-fold the cut-off value for anti-gE \[97 international units per liter (IU/L)\]. * For initially seropositive participants, anti-gE antibody concentration at post-vaccination \>= 4-fold the pre-vaccination anti-gE antibody concentration.
Time frame: At Month 2 and Month 3
Anti-gE Antibody Concentrations Expressed as Geometric Mean Concentrations (GMCs) as Determined by ELISA
Anti-gE antibody concentrations were determined by ELISA and expressed as GMCs in IU/L.
Time frame: At Day 1, Month 2 and Month 3
The study was conducted at 46 centers in 8 countries (Estonia, Finland, Hong Kong, Mexico, Panama, Russian Federation, Spain and United Kingdom).
| Milestone | HZ/su Group | Placebo Group |
|---|---|---|
| Started | 714 | 712 |
| Completed | 646 | 640 |
| Not completed | 68 | 72 |
| Withdrew: Adverse event | 15 | 10 |
| Withdrew: Lost to follow-up | 8 | 8 |
| Withdrew: Protocol violation | 5 | 4 |
| Withdrew: Withdrawal by subject | 21 | 27 |
| Withdrew: Non-emergency unblinding/non-compliance | 15 | 18 |
| Withdrew: Migrated/moved from the study area | 3 | 5 |
| Withdrew: Suspected hz episode | 1 | 0 |
A suspected case of HZ is defined as a new unilateral rash accompanied by pain (broadly defined to include allodynia, pruritus or other sensations) and no alternative diagnosis. A suspected case of HZ was confirmed by an algorithm that included Polymerase Chain Reaction (PCR) and the HZ Ascertainment Committee (HZAC) determination. The incidence rate (n/T) of confirmed HZ cases, expressed in terms of 1000 person-years rate, was calculated as the number of participants reporting at least one confirmed HZ case (n) in a group, over the sum of follow-up period expressed in years (T) in the same group, and multiplied by 1000.
| Cases per 1000 person-years | HZ/su Group | Placebo Group |
|---|---|---|
| Incidence Rate of Confirmed Herpes Zoster (HZ) Cases | 0.0 | 4.1 |
A suspected case of HZ is defined as a new unilateral rash accompanied by pain (broadly defined to include allodynia, pruritus or other sensations) and no alternative diagnosis. A suspected case of HZ was confirmed by an algorithm that included PCR and the HZAC determination. The incidence rate (n/T) of confirmed HZ cases, expressed in terms of 1000 person-years rate, was calculated as the number of participants reporting at least one confirmed HZ case (n) in a group, over the sum of follow-up period expressed in years (T) in the same group, and multiplied by 1000.
| Cases per 1000 person-years | HZ/su Group | Placebo Group |
|---|---|---|
| Incidence Rate of Confirmed HZ Cases | 0.0 | 3.6 |
Assessed solicited administration site events included erythema, pain, pruritus and swelling at the injection site. Any = occurrence of the event regardless of intensity grade. Grade 3 pain = significant pain at rest, which prevented normal, everyday activities. Grade 3 erythema, swelling = erythema, swelling with a surface diameter greater than (\>) 100 millimeters (mm). Grade 3 pruritus = itchy sensation that prevented normal, everyday activities.
| Participants | HZ/su Group | Placebo Group |
|---|---|---|
| Any Erythema, post-vaccination at Day 1 | 164 | 5 |
| Grade 3 Erythema, post-vaccination at Day 1 | 8 | 0 |
| Any Pain, post-vaccination at Day 1 | 562 | 61 |
| Grade 3 Pain, post-vaccination at Day 1 | 49 | 2 |
| Any Pruritus, post-vaccination at Day 1 | 148 | 24 |
| Grade 3 Pruritus, post-vaccination at Day 1 | 4 | 0 |
| Any Swelling, post-vaccination at Day 1 | 91 | 1 |
| Grade 3 Swelling, post-vaccination at Day 1 | 3 | 0 |
| Any Erythema, post-vaccination at Month 2 | 164 | 0 |
| Grade 3 Erythema, post-vaccination at Month 2 | 14 | 0 |
| Any Pain, post-vaccination at Month 2 | 503 | 48 |
| Grade 3 Pain, post-vaccination at Month 2 | 48 | 0 |
| Any Pruritus, post-vaccination at Month 2 | 142 | 10 |
| Grade 3 Pruritus, post-vaccination at Month 2 | 7 | 0 |
| Any Swelling, post-vaccination at Month 2 | 82 | 1 |
| Grade 3 Swelling, post-vaccination at Month 2 | 3 | 0 |
Duration is the number of days in which a participant experienced the symptom within the 7-day solicited follow-up period. Assessed solicited administration site events included erythema, pain, pruritus and swelling at the injection site.
| Days | HZ/su Group | Placebo Group |
|---|---|---|
| Erythema, post-vaccination at Day 1 | 3.0 (2.0 to 5.0) | 3.0 (2.0 to 4.0) |
| Pain, post-vaccination at Day 1 | 3.0 (2.0 to 4.0) | 1.0 (1.0 to 2.0) |
| Pruritus, post-vaccination at Day 1 | 2.0 (1.0 to 3.0) | 1.0 (1.0 to 3.0) |
| Swelling, post-vaccination at Day 1 | 3.0 (1.0 to 4.0) | 2.0 (2.0 to 2.0) |
| Erythema, post-vaccination at Month 2 | 3.0 (2.0 to 5.0) | — |
| Pain, post-vaccination at Month 2 | 3.0 (2.0 to 4.0) | 1.0 (1.0 to 2.0) |
| Pruritus, post-vaccination at Month 2 | 2.0 (1.0 to 3.0) | 1.0 (1.0 to 2.0) |
| Swelling, post-vaccination at Month 2 | 3.0 (2.0 to 4.0) | 6.0 (6.0 to 6.0) |
Assessed solicited systemic events included fatigue, fever (defined as axillary temperature greater than or equal to (\>=) 38.0°C/100.4°F), gastrointestinal symptoms, headache, malaise, myalgia, and shivering. Any = occurrence of the event regardless of intensity grade or relation to the study vaccination. Grade 3 = event that prevented normal, everyday activities. Grade 3 fever = axillary temperature higher than (\>) 39.0°C/102.2°F. Related = event assessed by the investigator as related to the study vaccination.
| Participants | HZ/su Group | Placebo Group |
|---|---|---|
| Any Fatigue, post-vaccination at Day 1 | 329 | 146 |
| Grade 3 Fatigue, post-vaccination at Day 1 | 42 | 10 |
| Related Fatigue, post-vaccination at Day 1 | 292 | 105 |
| Any Fever, post-vaccination at Day 1 | 26 | 4 |
| Grade 3 Fever, post-vaccination at Day 1 | 1 | 0 |
| Related Fever, post-vaccination at Day 1 | 26 | 4 |
| Any Gastrointestinal symptoms, post-vaccination at Day 1 | 103 | 79 |
| Grade 3 Gastrointestinal symptoms, post-vaccination at Day 1 | 8 | 4 |
| Related Gastrointestinal symptoms, post-vaccination at Day 1 | 84 | 54 |
| Any Headache, post-vaccination at Day 1 | 266 | 136 |
| Grade 3 Headache, post-vaccination at Day 1 | 21 | 11 |
| Related Headache, post-vaccination at Day 1 | 224 | 90 |
| Any Malaise, post-vaccination at Day 1 | 260 | 70 |
| Grade 3 Malaise, post-vaccination at Day 1 | 30 | 9 |
| Related Malaise, post-vaccination at Day 1 | 231 | 52 |
| Any Myalgia, post-vaccination at Day 1 | 262 | 65 |
| Grade 3 Myalgia, post-vaccination at Day 1 | 17 | 8 |
| Related Myalgia, post-vaccination at Day 1 | 240 | 45 |
| Any Shivering, post-vaccination at Day 1 | 185 | 43 |
| Grade 3 Shivering, post-vaccination at Day 1 | 16 | 0 |
| Related Shivering, post-vaccination at Day 1 | 174 | 36 |
| Any Fatigue, post-vaccination at Month 2 | 364 | 115 |
| Grade 3 Fatigue, post-vaccination at Month 2 | 59 | 10 |
| Related Fatigue, post-vaccination at Month 2 | 327 | 85 |
| Any Fever, post-vaccination at Month 2 | 66 | 5 |
| Grade 3 Fever, post-vaccination at Month 2 | 4 | 1 |
| Related Fever, post-vaccination at Month 2 | 63 | 3 |
| Any Gastrointestinal symptoms, post-vaccination at Month 2 | 118 | 54 |
| Grade 3 Gastrointestinal symptoms, post-vaccination at Month 2 | 11 | 4 |
| Related Gastrointestinal symptoms, post-vaccination at Month 2 | 102 | 37 |
| Any Headache, post-vaccination at Month 2 | 290 | 113 |
| Grade 3 Headache, post-vaccination at Month 2 | 30 | 6 |
| Related Headache, post-vaccination at Month 2 | 256 | 73 |
| Any Malaise, post-vaccination at Month 2 | 321 | 69 |
| Grade 3 Malaise, post-vaccination at Month 2 | 45 | 7 |
| Related Malaise, post-vaccination at Month 2 | 290 | 50 |
| Any Myalgia, post-vaccination at Month 2 | 294 | 54 |
| Grade 3 Myalgia, post-vaccination at Month 2 | 41 | 2 |
| Related Myalgia, post-vaccination at Month 2 | 269 | 40 |
| Any Shivering, post-vaccination at Month 2 | 253 | 32 |
| Grade 3 Shivering, post-vaccination at Month 2 | 37 | 2 |
| Related Shivering, post-vaccination at Month 2 | 234 | 28 |
Duration is the number of days in which a participant experienced the symptom within the 7-day solicited follow-up period. Assessed solicited systemic events included fatigue, fever (defined as axillary temperature \>=38.0°C/100.4°F), gastrointestinal symptoms, headache, malaise, myalgia and shivering.
| Days | HZ/su Group | Placebo Group |
|---|---|---|
| Fatigue, post-vaccination at Day 1 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 4.0) |
| Fever, post-vaccination at Day 1 | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) |
| Gastrointestinal symptoms, post-vaccination at Day 1 | 1.0 (1.0 to 3.0) | 2.0 (1.0 to 2.0) |
| Headache, post-vaccination at Day 1 | 2.0 (1.0 to 3.0) | 1.0 (1.0 to 3.0) |
| Malaise, post-vaccination at Day 1 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 4.0) |
| Myalgia, post-vaccination at Day 1 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 4.0) |
| Shivering, post-vaccination at Day 1 | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) |
| Fatigue, post-vaccination at Month 2 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 4.0) |
| Fever, post-vaccination at Month 2 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| Gastrointestinal symptoms, post-vaccination at Month 2 | 2.0 (1.0 to 3.0) | 1.0 (1.0 to 2.0) |
| Headache, post-vaccination at Month 2 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 2.0) |
| Malaise, post-vaccination at Month 2 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 4.0) |
| Myalgia, post-vaccination at Month 2 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 5.0) |
| Shivering, post-vaccination at Month 2 | 1.0 (1.0 to 2.0) | 2.0 (1.0 to 3.0) |
An unsolicited AE is defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event. Any = occurrence the event regardless of intensity grade or relation to the study vaccination. Grade 3 = event that prevented normal, everyday activities. Related = event assessed by the investigator as related to the study vaccination.
| Participants | HZ/su Group | Placebo Group |
|---|---|---|
| Any Unsolicited AEs, post-vaccination at Day 1 | 118 | 104 |
| Grade 3 Unsolicited AEs, post-vaccination at Day 1 | 12 | 10 |
| Related Unsolicited AEs, post-vaccination at Day 1 | 32 | 18 |
| Any Unsolicited AEs, post-vaccination at Month 2 | 120 | 116 |
| Grade 3 Unsolicited AEs, post-vaccination at Month 2 | 13 | 6 |
| Related Unsolicited AEs, post-vaccination at Month 2 | 33 | 7 |
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study participant. Any = occurrence of the SAE regardless of intensity grade or relation to the study vaccination. Related = SAE assessed by the investigator as related to the study vaccination.
| Participants | HZ/su Group | Placebo Group |
|---|---|---|
| Any SAEs | 11 | 11 |
| Related SAEs | 0 | 0 |
pIMDs are defined as a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any = occurrence of the pIMD regardless of intensity grade or relation to the study vaccination. Related = pIMD assessed by the investigator as related to the study vaccination.
| Participants | HZ/su Group | Placebo Group |
|---|---|---|
| Any pIMDs | 2 | 2 |
| Related pIMDs | 0 | 1 |
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study participant. Any = occurrence of the SAE regardless of intensity grade or relation to the study vaccination. Related = SAE assessed by the investigator as related to the study vaccination.
| Participants | HZ/su Group | Placebo Group |
|---|---|---|
| Any SAEs | 35 | 22 |
| Related SAEs | 0 | 0 |
pIMDs are defined as a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any = occurrence of the pIMD regardless of intensity grade or relation to the study vaccination. Related = pIMD assessed by the investigator as related to the study vaccination.
| Participants | HZ/su Group | Placebo Group |
|---|---|---|
| Any pIMDs | 2 | 5 |
| Related pIMDs | 0 | 0 |
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study participant. Any SAEs related to the investigational vaccine or related to study participation or to a GSK concomitant medication/vaccine as assessed by the investigator are reported.
| Participants | HZ/su Group | Placebo Group |
|---|---|---|
| Number of Participants With SAEs Related to Investigational Vaccine, Related to Study Participation or to GSK Concomitant Medication/Vaccine | 1 | 1 |
Vaccine response for anti-gE antibodies is defined as: * For initially seronegative participants, anti-gE antibody concentration at post-vaccination \>= 4-fold the cut-off value for anti-gE \[97 international units per liter (IU/L)\]. * For initially seropositive participants, anti-gE antibody concentration at post-vaccination \>= 4-fold the pre-vaccination anti-gE antibody concentration.
| Percentage of participants | HZ/su Group | Placebo Group |
|---|---|---|
| At Month 2 | 85.8 (82.8 to 88.5) | 0.2 (0.0 to 0.9) |
| At Month 3 | 95.3 (93.1 to 96.9) | 0.2 (0.0 to 1.1) |
Anti-gE antibody concentrations were determined by ELISA and expressed as GMCs in IU/L.
| IU/L | HZ/su Group | Placebo Group |
|---|---|---|
| At Day 1 | 2151.30 (2004.22 to 2309.17) | 2087.14 (1942.47 to 2242.58) |
| At Month 2 | 24346.52 (22840.59 to 25951.74) | 1850.11 (1725.86 to 1983.30) |
| At Month 3 | 49175.78 (46500.40 to 52005.09) | 1849.08 (1718.02 to 1990.13) |
Collected over Solicited AEs: within 7 days after any vaccination. Unsolicited AEs: within 30 days after any vaccination. All-cause mortality & SAEs: from first vaccination (Day 1) until study end (duration of approximately 2 years to 4 years and 5 months). pIMDs: from first vaccination (Day 1) until 1 year post-last vaccination (last vaccination administered at Day 1 for participants who received only 1 dose and at Month 2 for participants who received 2 doses).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HZ/su Group | 12/714 (1.7%) | 56/714 (7.8%) | 665/714 (93.1%) |
| Placebo Group | 8/712 (1.1%) | 43/712 (6%) | 414/712 (58.1%) |
| Event | HZ/su Group | Placebo Group |
|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 4/714 | 5/712 |
| PneumoniaInfections and infestations | 4/714 | 2/712 |
| COVID-19Infections and infestations | 3/714 | 1/712 |
| Cardiac failureCardiac disorders | 2/714 | 2/712 |
| Myocardial infarctionCardiac disorders | 2/714 | 2/712 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/714 | 2/712 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/714 | 2/712 |
| Ischaemic strokeNervous system disorders | 0/714 | 2/712 |
| Cardiac arrestCardiac disorders | 2/714 | 1/712 |
| CellulitisInfections and infestations | 2/714 | 0/712 |
| Event | HZ/su Group | Placebo Group |
|---|---|---|
| Administration site painGeneral disorders | 611/714 | 94/712 |
| FatigueGeneral disorders | 457/714 | 199/712 |
| MalaiseGeneral disorders | 396/714 | 112/712 |
| MyalgiaMusculoskeletal and connective tissue disorders | 389/714 | 97/712 |
| HeadacheNervous system disorders | 384/714 | 201/712 |
| ChillsGeneral disorders | 330/714 | 64/712 |
| Administration site erythemaGeneral disorders | 238/714 | 5/712 |
| PruritusSkin and subcutaneous tissue disorders | 228/714 | 33/712 |
| Gastrointestinal disorderGastrointestinal disorders | 179/714 | 117/712 |
| Administration site swellingGeneral disorders | 133/714 | 2/712 |
| Age, Continuous(Years) | HZ/su Group | Placebo Group | Total |
|---|---|---|---|
| Mean | 64.2 ± 8.5 | 64.1 ± 8.8 | 64.1 ± 8.6 |
| Sex: Female, Male(Participants) | HZ/su Group | Placebo Group | Total |
|---|---|---|---|
| Female | 430 | 434 | 864 |
| Male | 284 | 278 | 562 |
| Ethnicity (NIH/OMB)(Participants) | HZ/su Group | Placebo Group | Total |
|---|---|---|---|
| Hispanic or Latino | 80 | 77 | 157 |
| Not Hispanic or Latino | 634 | 635 | 1269 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Sep 2019 to primary completion in Feb 2024, 52 months.
Results were first posted in Mar 2025, 1 year 1 month after primary completion.
Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 52 months is above that.
Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Shingrix